Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia. / Marthin, June K.; Nielsen, Kim G.; Mortensen, Jann.

I: ERJ Open Research, Bind 9, Nr. 5, 00345-2023, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Marthin, JK, Nielsen, KG & Mortensen, J 2023, 'Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia', ERJ Open Research, bind 9, nr. 5, 00345-2023. https://doi.org/10.1183/23120541.00345-2023

APA

Marthin, J. K., Nielsen, K. G., & Mortensen, J. (2023). Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia. ERJ Open Research, 9(5), [00345-2023]. https://doi.org/10.1183/23120541.00345-2023

Vancouver

Marthin JK, Nielsen KG, Mortensen J. Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia. ERJ Open Research. 2023;9(5). 00345-2023. https://doi.org/10.1183/23120541.00345-2023

Author

Marthin, June K. ; Nielsen, Kim G. ; Mortensen, Jann. / Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia. I: ERJ Open Research. 2023 ; Bind 9, Nr. 5.

Bibtex

@article{8aeadae8dbb4407c90f1e06dc4c15d3e,
title = "Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia",
abstract = "Background Primary ciliary dyskinesia (PCD) is an inherited disorder in which dyskinetic cilia cause impaired mucociliary clearance of upper and lower airways. Airway ciliary movement can be indirectly tested in vivo after administration of a radiolabelled tracer to the lower airways for assessment of pulmonary mucociliary clearance or to the nose for assessing nasal mucociliary clearance (NMC). With this study, we investigated NMC as a quantifiable study outcome parameter in patients with PCD. Material and methods This single centre proof-of-concept study on NMC velocity investigated patients with PCD across different genotypes and nasal nitric oxide (nasal NO) levels. Healthy controls were used for comparison. NMC was determined as velocity in mm·min−1 of a nasally applied99mTc-albumin colloid tracer. Using a gamma camera, repeated dynamic series of images each lasting 30 s were acquired during a 10-minute period and digitally stored. Results NMC velocity was investigated in seven patients with PCD (aged 9–31 years) and five adult healthy controls. Mean NMC velocity in healthy controls (8.5 mm·min−1) was significantly higher compared with people with PCD (0.00 mm·min−1, p<0.0001). NMC was completely absent in all included patients with PCD across different PCD genotypes and regardless of nasal NO values. The success rate of the test was 100% in both groups. Conclusion NMC velocity discriminated highly significantly between patients with PCD and healthy controls. We suggest here a fast and feasible set up for NMC measurements that is easily applicable for any clinical trial involving PCD medication aimed for the nasal compartment, a step before or parallel to conducting clinical trials investigating whole-lung ciliary function in PCD.",
author = "Marthin, {June K.} and Nielsen, {Kim G.} and Jann Mortensen",
note = "Publisher Copyright: {\textcopyright} The authors 2023.",
year = "2023",
doi = "10.1183/23120541.00345-2023",
language = "English",
volume = "9",
journal = "ERJ Open Research",
issn = "2312-0541",
publisher = "ERS publications",
number = "5",

}

RIS

TY - JOUR

T1 - Quantitative99mTc-albumin colloid nasal mucociliary clearance as an outcome in primary ciliary dyskinesia

AU - Marthin, June K.

AU - Nielsen, Kim G.

AU - Mortensen, Jann

N1 - Publisher Copyright: © The authors 2023.

PY - 2023

Y1 - 2023

N2 - Background Primary ciliary dyskinesia (PCD) is an inherited disorder in which dyskinetic cilia cause impaired mucociliary clearance of upper and lower airways. Airway ciliary movement can be indirectly tested in vivo after administration of a radiolabelled tracer to the lower airways for assessment of pulmonary mucociliary clearance or to the nose for assessing nasal mucociliary clearance (NMC). With this study, we investigated NMC as a quantifiable study outcome parameter in patients with PCD. Material and methods This single centre proof-of-concept study on NMC velocity investigated patients with PCD across different genotypes and nasal nitric oxide (nasal NO) levels. Healthy controls were used for comparison. NMC was determined as velocity in mm·min−1 of a nasally applied99mTc-albumin colloid tracer. Using a gamma camera, repeated dynamic series of images each lasting 30 s were acquired during a 10-minute period and digitally stored. Results NMC velocity was investigated in seven patients with PCD (aged 9–31 years) and five adult healthy controls. Mean NMC velocity in healthy controls (8.5 mm·min−1) was significantly higher compared with people with PCD (0.00 mm·min−1, p<0.0001). NMC was completely absent in all included patients with PCD across different PCD genotypes and regardless of nasal NO values. The success rate of the test was 100% in both groups. Conclusion NMC velocity discriminated highly significantly between patients with PCD and healthy controls. We suggest here a fast and feasible set up for NMC measurements that is easily applicable for any clinical trial involving PCD medication aimed for the nasal compartment, a step before or parallel to conducting clinical trials investigating whole-lung ciliary function in PCD.

AB - Background Primary ciliary dyskinesia (PCD) is an inherited disorder in which dyskinetic cilia cause impaired mucociliary clearance of upper and lower airways. Airway ciliary movement can be indirectly tested in vivo after administration of a radiolabelled tracer to the lower airways for assessment of pulmonary mucociliary clearance or to the nose for assessing nasal mucociliary clearance (NMC). With this study, we investigated NMC as a quantifiable study outcome parameter in patients with PCD. Material and methods This single centre proof-of-concept study on NMC velocity investigated patients with PCD across different genotypes and nasal nitric oxide (nasal NO) levels. Healthy controls were used for comparison. NMC was determined as velocity in mm·min−1 of a nasally applied99mTc-albumin colloid tracer. Using a gamma camera, repeated dynamic series of images each lasting 30 s were acquired during a 10-minute period and digitally stored. Results NMC velocity was investigated in seven patients with PCD (aged 9–31 years) and five adult healthy controls. Mean NMC velocity in healthy controls (8.5 mm·min−1) was significantly higher compared with people with PCD (0.00 mm·min−1, p<0.0001). NMC was completely absent in all included patients with PCD across different PCD genotypes and regardless of nasal NO values. The success rate of the test was 100% in both groups. Conclusion NMC velocity discriminated highly significantly between patients with PCD and healthy controls. We suggest here a fast and feasible set up for NMC measurements that is easily applicable for any clinical trial involving PCD medication aimed for the nasal compartment, a step before or parallel to conducting clinical trials investigating whole-lung ciliary function in PCD.

U2 - 10.1183/23120541.00345-2023

DO - 10.1183/23120541.00345-2023

M3 - Journal article

C2 - 37701364

AN - SCOPUS:85171853281

VL - 9

JO - ERJ Open Research

JF - ERJ Open Research

SN - 2312-0541

IS - 5

M1 - 00345-2023

ER -

ID: 387833345